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Abstract
Background: Bell’s palsy is an idiopathic condition, caused by inflammatory injury to the facial nerve,
resulting in a unilateral facial paralysis. This disfiguring disorder affects about 40 000 people in the U.S. each
year and although many recover without treatment, there are serious physical and psychological
complications for those that fail to recover completely. Due to its unknown etiology, the preferred treatment
of Bell’s palsy has been the subject of controversy for sometime. Current practice has demonstrated the use of
steroids to counteract the inflammatory process and/or antivirals because of a hypothesized viral etiology.
Does the use of antivirals alone or in conjunction with steroids substantially increase the overall recovery in
patients with Bell’s palsy?
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL-EBSCOhost, EBMR
Multifile, and Web of Science using the keywords: Bell’s palsy, antiviral agents and prednisone or
prednisolone. The NIH clinical trials site revealed no on-going or registered trials comparing the treatment of
steroids and antivirals in patients with Bell’s palsy. Relevant articles were assessed for quality using GRADE.
Results: Two randomized, double blind, placebo-controlled trials were included in this systematic review.
One trial, with 829 participants, demonstrated a statistically significant increase in the recovery of patients
treated with prednisolone as compared to valaciclovir. A second trial, with 496 participants, demonstrated a
statistically significant increase in the recovery of patients treated with prednisolone as compared to aciclovir.
Conclusion: When initiated within 72 hours of symptom onset, prednisone has been shown to increase the
overall number and rate of recoveries in patients being treated for Bell’s palsy. The use of antivirals alone, as
compared to placebo, did not increase the number of recoveries and in some cases slowed the rate at which
patients recovered. Furthermore, when compared to prednisone alone, these two trials failed to produce
results of statistically significant improvement in recovery when administering combination therapy of
prednisone plus antivirals. This raises question as to whether combination therapy should be considered at all
until further research proves a statistically significant improvement or a true etiology for Bell’s palsy is
identified.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
Keywords
Bell’s palsy, Antiviral agents, Prednisone, Prednisolone
Subject Categories
Medicine and Health Sciences
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/428
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/428
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/428
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
 - 1 -  
 
The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients 
With Bell’s Palsy: A Systematic Review 
 
 
 
 
 
 
 
 
 
Robin J. Tyner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR  
For the Masters of Science Degree, August 10, 2013 
 
Faculty Advisor: Robert Rosenow, Pharm.D., O.D. 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
 
 
 - 2 -  
Biography 
Robin Tyner is a native of Texas.  She received a Bachelors of Science degree with an 
emphasis in Health Sciences from Pacific University, Oregon, in 2012.  Prior to PA 
school, she worked as a medical assistant at a hospital in San Antonio and served as a 
medic in the United States Army for 5 years.  During her deployment to Iraq she worked 
with superbly skilled clinicians that enjoyed teaching, and had her dream of pursuing a 
career as a PA solidified.  She is interested in serving the under-served and pursuing a 
career in Emergency Medicine.
 - 3 -  
 
Abstract   
Background:  Bell’s palsy is an idiopathic condition, caused by inflammatory injury to 
the facial nerve, resulting in a unilateral facial paralysis. This disfiguring disorder affects 
about 40 000 people in the U.S. each year and although many recover without treatment, 
there are serious physical and psychological complications for those that fail to recover 
completely.  Due to its unknown etiology, the preferred treatment of Bell’s palsy has 
been the subject of controversy for sometime. Current practice has demonstrated the use 
of steroids to counteract the inflammatory process and/or antivirals because of a 
hypothesized viral etiology.  Does the use of antivirals alone or in conjunction with 
steroids substantially increase the overall recovery in patients with Bell’s palsy?  
 
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL-
EBSCOhost, EBMR Multifile, and Web of Science using the keywords: Bell’s palsy, 
antiviral agents and prednisone or prednisolone.  The NIH clinical trials site revealed no 
on-going or registered trials comparing the treatment of steroids and antivirals in patients 
with Bell’s palsy.  Relevant articles were assessed for quality using GRADE.  
 
Results: Two randomized, double blind, placebo-controlled trials were included in this 
systematic review. One trial, with 829 participants, demonstrated a statistically 
significant increase in the recovery of patients treated with prednisolone as compared to 
valaciclovir. A second trial, with 496 participants, demonstrated a statistically significant 
increase in the recovery of patients treated with prednisolone as compared to aciclovir.  
 
Conclusion:  When initiated within 72 hours of symptom onset, prednisone has been 
shown to increase the overall number and rate of recoveries in patients being treated for 
Bell’s palsy.  The use of antivirals alone, as compared to placebo, did not increase the 
number of recoveries and in some cases slowed the rate at which patients recovered.  
Furthermore, when compared to prednisone alone, these two trials failed to produce 
results of statistically significant improvement in recovery when administering 
combination therapy of prednisone plus antivirals.  This raises question as to whether 
combination therapy should be considered at all until further research proves a 
statistically significant improvement or a true etiology for Bell’s palsy is identified.     
 
Keywords: Bell’s palsy, Antiviral agents and Prednisone or Prednisolone 
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The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients 
With Bell’s Palsy: A Systematic Review  
BACKGROUND 
Bell’s palsy, or idiopathic unilateral facial nerve paralysis, is a disfiguring 
disorder that acutely affects approximately 40 000 Americans each year.1  This condition 
is characterized by an inflammatory injury to the facial nerve, which renders the muscles 
of facial expression that it innervates, either partially or completely paralyzed.  Although 
many patients can recover without intervention, up to 30% of the 15 to 30 new cases per 
100 000 population reported worldwide annually suffer incomplete recovery or sequelae.2  
In turn, those who do not fully recover may experience psychological effects due to a 
perceived loss of beauty and function as a result of prolonged or permanent facial 
asymmetry.   
The exact etiology of Bell’s palsy (BP) remains unknown, but the accepted 
pathophysiology supports an inflammatory mechanism that compresses the seventh 
cranial nerve around the area where it exits the skull via the stylomastoid foramen.  Upon 
exiting the skull, the facial nerve travels through the fallopian canal and then enters the 
parotid gland where it divides into the five terminal branches that are responsible for 
innervating the muscles of facial expression.3  Inflammation of the nerve itself, or 
anything else running inside the narrow canal, has the ability to compress and damage the 
facial nerve, resulting in weakness or paralysis of everything that it innervates.  In 
addition to the muscles of facial expression, the nerve also stimulates secretions of the 
lower jaw, tear glands, and salivary glands, and is also responsible for taste sensation to 
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the anterior 2/3rds of the tongue as well as perceived sound volume.4 All of the structures 
that the facial nerve innervates account for the classic presentation associated with this 
condition.   
The classic presentation of BP most often includes rapid onset of upper and lower 
facial paralysis which is typically unilateral and may also include post-auricular pain, 
decreased tearing, hyperacusis, alteration of taste and/or otalgia.2  Patients often present 
with complaints of an inability to smile, raise their eyebrow or blink naturally on the 
affected side.  It is not uncommon for patients to have the affected eye roll upward on its 
own, in attempts to close their eye, which is known as Bell’s phenomenon.  To accurately 
be diagnosed as BP, the paralysis must include both the lower portion of the face and the 
forehead.  The onset of symptoms can be frightening as they often peak in less than 48 
hours and, to an untrained eye, can mimic those of a stroke or central motor neuron 
lesion.  It is important to be able to differentiate between a central motor neuron lesion, 
which is more serious and BP, which is a peripheral lower motor neuron lesion.  Patients 
presenting with a history of gradual onset, ability to raise their eyebrow on the affected 
side and contralateral weakness should be worked up thoroughly to rule out a central 
lesion or stroke.2 
The diagnosis is often one of exclusion, based on a careful history and physical 
exam, as there are no specific diagnostic tests for BP.  Prognosis and treatment choices 
are often guided by the severity of the paralysis, which can be assessed using a number of 
different scales including the House-Brackmann scale (HBS), the Sunnybrook scale (SS) 
or the Yanigahara scale (YS).  The HBS and SS have been more widely used in the U.S. 
and Europe whereas the YS has been used most frequently in Japan.  The HBS is a scale, 
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with grades I to VI, used to assess facial nerve function from three different standpoints, 
which include gross appearance, at rest, and in motion.  Grade I indicates normal function 
in all branches, grade II indicates slight weakness or asymmetry, grade III indicates 
obvious weakness that is not disfiguring, grade IV in indicative of disfigurement with 
obvious weakness, grade V is considered severe with movement being barely perceptible, 
and grade VI indicates a complete lack of facial function altogether with no movement 
being visible at all.5 The SS is a scale that grades facial nerve function on a score from 1 
to 100, with three domains, that includes resting symmetry, symmetry of voluntary 
movement and synkinesis.  For resting symmetry, the eye, nasolabial fold and mouth of 
the affected side are compared with the normal side.  The voluntary movements and 
synkinesis domains evaluate brow lift, gentle eye closure, open mouth smile, snarl, and 
lip pucker.6 These methods for grading severity have also been proven to be useful tools 
in documenting the recovery progress of individuals with BP.   
Due to its unknown etiology, the preferred treatment of Bell’s palsy has been the 
subject of controversy for sometime.  Current practice has demonstrated the use of 
steroids to counteract the inflammatory process and/or antivirals because of a 
hypothesized viral etiology, namely Herpes Simplex Virus-1 (HSV1).7  Prednisone and 
prednisolone are analogues of one another that have been used as the steroid of choice for 
BP.  To date, many randomized controlled trials (RCTs) have studied the efficacy of both 
steroids and antivirals, individually, as well as in combination.  The study of antivirals in 
the treatment of BP has included the use of acyclovir/aciclovir, valacycolvir/valaciclovir 
and more recently famciclovir.  “Valacyclovir is a prodrug and is nearly completely 
converted to acyclovir and L-valine.  The bioavailability of valacyclovir is 3-5 times that 
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of acyclovir, implying a much higher antiviral activity against HSV.”8 The controversy 
around the etiology of this condition, its treatment and the many clinical trials out there 
with conflicting results gave rise to the review of this clinical question.  Is mono-therapy 
with prednisone or antivirals more efficacious in the complete recovery of patients with 
Bell’s palsy than combination therapy?   
METHODS 
  An exhaustive search was conducted using the search engines Medline-OVID, 
CINAHL-EBSCOhost, EBMR Multifile, and Web of Science.  Keywords such as Bell’s 
palsy, antiviral agents, and prednisone or prednisolone were used.  The search was then 
narrowed to include only those trials that were conducted on humans, and published in 
English, within the last five years.  Articles with primary data evaluating the efficacy of 
prednisone or prednisolone versus antiviral agents in the treatment of patients with new 
onset Bell’s palsy were included for review.  The relevant articles were then critically 
appraised to assess for validity, and risk of bias, and to determine if they met pre-
specified inclusion criteria for eligibility.  To meet inclusion criteria, the studies had to be 
based on RCTs that had blind assessment of outcome and initiated treatment within 72 
hours of symptom onset.  The relevant articles, which met eligibility criteria, were then 
assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE).9  Lastly, a search on the National Institute of Health (NIH) 
clinical trials site revealed no currently registered trials, at any phase, relating to the use 
of steroids or antivirals in the treatment of Bell’s palsy. 
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RESULTS 
  The initial result of the search yielded 56 articles for review.  After narrowing the 
original search with the aforementioned criteria, there were 31 articles that underwent 
further screening.  After removing duplicates and irrelevant articles, six articles based on 
randomized controlled trials were critically appraised for validity and two of those met 
eligibility inclusion criteria.  The two articles, which met inclusion criteria, were 
Engström et al (2008)10, which was conducted in Sweden, and Sullivan et al (2009)11, 
which was conducted in Scotland (see Table I).  The authors of the four excluded articles 
were Hato et al (2007)8, Kawaguchi et al (2007)12, Minnerop et al (2008)13, and Yeo et al 
(2008).14  The exclusion of these fours studies was due to failure to blind or enrollment of 
some participants who had treatment initiated after the 72 hour cut-off mark.      
Engström et al  
  This randomized, double blind, placebo-controlled trial10 investigated the short 
and long-term effects of valaciclovir and prednisolone in the recovery of the facial nerve 
of patients with BP.  This study was set in Sweden and included 839 patients, aged 18 to 
75 that presented, or were referred from EDs, or general practitioners within 72 hours of 
symptom onset of BP.  Patients were considered ineligible, and therefore excluded, if 
they had had BP previously, waited more than 72 hours to seek care, did not fit the age 
range, were already taking antivirals or had signs of other infections known to contribute 
to facial paralysis.  Additionally, patients were excluded if they had contraindications to 
any of the medications due to pre-existing health conditions such as peptic ulcer disease, 
recent head injury, renal or hepatic dysfunction, or were pregnant and or breastfeeding.10 
 - 11 -  
Once deemed eligible, patients were randomly assigned to one of four treatment 
groups by way of factorial method, via computer generation, that randomly selected 
groups of eight.   The four treatment groups included double placebo (OO), prednisolone 
plus placebo (OP), valaciclovir plus placebo (VO) and prednisolone plus valaciclovir 
(VP).  Patients allocated to receive prednisolone were given 60mg per day for five days 
and then had their dose reduced by 10mg each day for a total treatment time of 10 days.  
Patients allocated to receive valaciclovir were given 1000mg of valaciclovir three times 
per day for a total treatment time of 7 days.  A bottle of prednisolone or its placebo, and 
valaciclovir or its placebo, was given to each patient in accordance with his or her group 
designation.  Placebos were made to have the same smell, color and size of the drug it 
was mimicking, ensuring that patients were blind to their treatment group allocation.  
Additionally, study drugs were sealed in sequentially numbered, identical containers in 
accordance with allocation sequence and distributed in sealed envelopes that contained 
the randomization codes to ensure blinding of all study personnel and data analysts until 
all patients had completed follow-up.10 
Compliance was evaluated by counting the tablets in each container at each 
follow-up visit.  Follow-up visits were conducted to assess progression or improvement 
of facial function using the HBS and SS scales at days 11 and 17, and monthly for 
months 1, 2, 3, 6 and 12.  Although secondary outcomes such as facial function and 
synkinesis were evaluated, the primary endpoint was defined as time to complete 
recovery of facial recovery.  Complete recovery was determined by a grade of I on the 
HBS or a score of 100 on the SS.  In addition, data were collected on adverse events 
experienced during treatment, which included but was not limited to, palpitations, 
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headache, fatigue, dizziness, paraesthesia, gastrointestinal complaints, and polyuria.10 
  Of the 829 patients who took any medication at all, 206 patients received OO, 210 
received OP, 207 received VO and 206 received VP.  Therefore, 416 patients received 
prednisolone and 413 received valaciclovir.  Patients were analyzed by whether or not 
they received prednisolone or valaciclovir using an intention to treat method. In addition, 
they were also analyzed in their individual group allocations so that data could be 
compared to establish the difference in effect between the two drugs as well as the effect 
of combining the two treatments against placebo.  The time to complete recovery was 
much shorter (75 days) for the 416 patients that received prednisolone compared with the 
413 patients that did not (135 days).   Additionally, it was noted that those patients who 
received double placebo experienced a complete recovery in about 104 days on average, 
which was nearly 1 month sooner than those treated with the antivirals.  Furthermore, of 
the patients treated with OP, 160/210 (76%) had a complete recovery at 12 months, 
which was significantly more when compared with the 133/207 (64%) receiving VO and 
the 133/206 (65%) receiving OO (see Table II).  These statistics correlate with a number 
needed to treat (NNT) with prednisolone, when compared with antivirals or placebo, of 
eight to see one additional complete recovery, which is statistically significant.10  
Sullivan et al 
 This randomized, double blind, placebo-controlled trial11 sought to determine 
whether the early use of oral prednisone or aciclovir, used separately or in combination, 
improved the recovery of patients with BP at three and nine months.  This study was set 
in Scotland and included 551 patients, aged 16 years and older, that were referred to 17 
different hospital trial sites from general practices with new onset of BP.  Patients were 
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considered ineligible, and therefore excluded, if they had had BP previously, waited more 
than 72 hours to seek care, did not fit the age range, were already taking antivirals or had 
signs of other infections known to contribute to facial paralysis.  Additionally, patients 
were excluded if they had contraindications to any of the medications due to pre-existing 
health conditions such as peptic ulcer disease, multiple sclerosis, uncontrolled diabetes, 
sarcoidosis, and herpes zoster, or were pregnant and or breastfeeding.11 
 Once deemed eligible, patients were randomly assigned to one of four treatment 
groups by an independent, secure, automated telephone service using a permuted block 
randomization technique without stratification and block sizes of 4 or 8.   The four 
treatment groups included double placebo (OO), prednisolone plus placebo (OP), 
aciclovir plus placebo (AO) and prednisolone plus aciclovir (AP).  All patients were 
treated for 10 days and those allocated to receive prednisolone were given enough 25mg 
tablets to take 50mg per day.  Patients allocated to receive aciclovir were given enough 
400mg tablets to take 2000mg each day.  A bottle of prednisolone or its placebo, and 
aciclovir or its placebo, was given to each patient in accordance with his or her group 
designation.  Placebos were indistinguishable in appearance from their respective drugs 
and with regard to their bottle packaging.  Each of the different treatment combinations 
was provided in packs labeled 1 through 4 to ensure that the referrers, recruiters, patients, 
researchers, and later, assessors were all blinded to treatment allocation and outcome.11   
The primary outcome, complete recovery of the facial nerve, was measured in this 
trial using the HBS.  After diagnosis, all patients were re-assessed in an at home visit, 3 
to 5 days post randomization into the trial.  Further follow-up and assessment was 
conducted at three months and again at nine months if a patient had not completely 
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recovered at the three-month visit.  Although a complete recovery of facial function was 
initially defined, by this trial, as an HBS score of II or better, the cutoff was changed to a 
score of I shortly after the study commenced.  Therefore, anyone with a score of II or 
higher at their three month follow-up visit was scheduled for a nine month visit.  
Judgments of recovery were determined by expert medical review of four posed portrait 
photographs taken at each follow-up visit.  The four photographed positions, utilized to 
evaluate the progression of recovery for each patient, were at rest, smiling, eyebrows 
raised and eyes tightly shut.  Three different clinicians (a plastic surgeon, neurologist and 
otolaryngologist) independently graded the photos of each patient.  Where difference of 
more than one point occurred between evaluators, the grading was redone.  Secondary 
outcomes that were evaluated included pain associated with the palsy, cost of the 
different treatment modalities and psychological distress associated with concern about 
personal appearance. Furthermore, the trial collected and analyzed data on all adverse 
events that were experienced with each individual or combined pharmaceutical treatment.  
These included, but were not limited to, nausea, vomiting, night sweats, and pruritus.11    
Of the 551 patients that were originally randomized, final outcomes were 
available for 496 patients, resulting in a 90% completion rate and 10% loss to follow-up 
overall.  Intention to treat analyses were conducted for all four treatment groups 
individually, as well as for combined grouping, to assess the difference in treatment 
effect for those receiving prednisolone as compared to those receiving antiviral treatment.  
For the three month follow-up appointment, approximately 86% of patients (107/124) 
that received OP had made a full recovery, which was significantly more than the 63% 
(75/120) that received AO and the 65% (77/119) that received OO (see Table II).  These 
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numbers correlated to a NNT with prednisolone in order to see one additional 
improvement of six patients at three months and an NNT of eight patients at nine months.  
The collected data from this trial did not correlate with a statistical significance between 
the placebo group as compared with the antiviral group.  In addition to the percentage of 
full recoveries, the authors of this study also analyzed the average time that it took each 
individual treatment group to achieve complete recovery.  That analysis found that 
treatment with prednisolone substantially shortened the duration of time needed to make 
a full recovery.  The mean time to full recovery for the OP group was 67 days as 
compared to 85 days for the AP group, 126 days for the OO group and 150 days for the 
AO group.11  
DISCUSSION 
Corticosteroids, namely prednisone or prednisolone, have proven to be both cost 
effective and very successful in the treatment of patients with Bell’s palsy.  Due to its 
idiopathic nature and proposed viral etiology, recent research has revolved around 
studying the use of antivirals alone or in conjunction with steroids for the treatment of 
BP.  To date, cost effectiveness aside, RCTs have produced conflicting results regarding 
the benefit of treating BP patients with antivirals alone or in conjunction with 
corticosteroids.  Both and Engström et al10 and Sullivan et al11 determined that the use of 
prednisolone was superior to either antiviral drug evaluated.  There was a significant 
difference in complete recovery as early on as 3 months in the groups that received 
prednisolone with both trials.  This trend continued to show statistically significant 
differences at all points of follow-up as evidenced in the Summary of Findings, which 
can be found in Table II.10,11  
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Both Engström10 and Sullivan et al11 reported an absence of statistical 
significance in the difference found between patients that received an antiviral plus 
placebo and those that received double placebo.  Furthermore, there was a decrease in the 
recovery rate for patients that received an antiviral in both trials.  This decrease balanced 
out to an equal recovery by the completion of the Engström et al study10 but continued to 
increase as time went on in the Sullivan et al study.  This data indicates a need for further 
research to be conducted before giving serious consideration to the prescription of 
antivirals at all.   Although neither of these studies determined that adding an antiviral to 
placebo was beneficial, there is room for more research to be done with regard to 
serological studies determining an underlying cause of Bell’s palsy.  Sullivan et al sited 
an area of further research opportunity to be in determining if higher tissue 
concentrations (higher doses) of antiviral agents could result in a more detectable benefit 
than that which they were able to find.10,11 
Additionally, systematic reviews and meta-analyses on variations of this subject 
have been published recently utilizing different eligibility criteria and quality 
stipulations.15-18 The eligibility criteria for inclusion in this review was slightly different 
than that of those reviews or analyses and, therefore, revealed some different articles for 
consideration.  Of the studies reviewed in consideration for this review, there were four 
RCTs that were assessed for quality of evidence in addition to the two, which were 
included in this review.  Although those four failed to meet all of the inclusion criteria, 
they served to gauge the strength or quality of evidence produced by the two articles that 
did meet all eligibility criteria.  
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The Hato et al study (2007)8 failed to meet inclusion criteria because it initiated 
treatment up to seven days after the onset of symptoms.  Nonetheless, the authors 
reported a slight increase in the recovery of 221 patients with BP that received 
combination therapy of valacyclovir and prednisolone when compared to prednisolone 
alone.  However, 52/296 (>17%) of the patients, who were originally randomized to 
receive treatment were lost to follow-up without explanation.  Furthermore, the 
physicians were not completely blinded during the trial limiting the strength or value of 
the study because of failure to uphold allocation concealment.8 
The Kawaguchi et al study (2007)12 was another RCT that failed to meet the 
inclusion criteria because it also initiated treatment up to seven days after the onset of 
initial symptoms.  This study evaluated the etiology of BP and sought to determine the 
effectiveness of valacyclovir and prednisone in treating it.  This RCT found no statistical 
difference in cumulative recovery rates between those treated with combination therapy 
and prednisolone alone.  However, this trial failed to blind the patients or physicians 
evaluating the progress of those enrolled in the study.  This limited the results of the 
study because it introduced bias.12 
The Minnerop et al study (2008)13 failed to meet inclusion criteria as they 
initiated treatment up to five days after initial symptom onset.  This study evaluated the 
combination therapy of famciclovir and prednisone in the treatment of patients with BP.  
Similar to valacyclovir, famcyclovir is another anologue of acyclovir, which is regarded 
to have greater bioavailability and therefore to be more effective overall.  Minnerop et 
al13 reported a significantly better outcome for BP patients treated with combination 
therapy as compared with prednisone alone.  However, the design of this study utilized 
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pseudo-randomization and failed to blind patients to their treatment group allocation.  
Additionally, 48/167 (30%) patients that were randomized were lost during follow-up, 
which severely limited the usefulness of this study.13  
The Yeo et al study (2008)14 also failed to meet inclusion criteria due to initiation 
of treatment greater than 72 hours after onset of symptoms and because other treatment 
mechanisms were also employed during this study.  The design of this study differed 
from all others in that all patients were admitted to the hospital for at least seven days to 
receive treatment.  Participants were given either prednisone and acyclovir or prednisone 
alone.  Additionally, the patients were also administered peripheral blood circulation 
supplements, plasma volume extenders and also received physical therapy services.  Yeo 
et al reported a greater recovery for those that received combination therapy as compared 
to prednisone alone.  However, they had a very small sample size of patients (n=91) and 
admittedly reported that the differences they found were not statistically significant.  
Furthermore, no discussion was made as to how allocation was concealed or whether or 
not a placebo was used to increase blinding.  All of these factors grossly limited the 
results of this study.14 
Due to the conflicting outcomes of the many RCTs conducted to date, including 
those above, it is imperative that one considers the quality of evidence for each study 
before basing clinical decisions on the information it provides.  Engström et al10 and 
Sullivan et al11 had superior methodology when compared to any of the other trials 
considered for this review.  The Engström et al10 study was a well-conducted study with a 
large sample size and complete follow-up.  Approximately ninety percent (743/829) of 
patients attended 12-month follow-up accounting for 90% completion and only a 10% 
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loss to follow-up overall.  Additionally, 728 of 829 patients returned no excess 
medication resulting in an 88% complete compliance rate.  Furthermore, 96% of patients 
were more than 80% compliant with taking their medication and there were only 16 
patients for which compliance data was missing.  Sullivan et al11 was also a well-
conducted study with a large sample size and complete follow-up.  Ninety percent of the 
patients (496/551) randomized to receive treatment completed follow-up, accounting for 
only 10% lost to follow-up.  A strength for both of these trials was that the authors of 
each study acknowledged and addressed their losses to follow-up.  Another strength of 
both trials was that they both employed otolaryngologists to assess all participants being 
admitted into the trials to ensure that they didn’t meet any of the exclusion criteria.  
Additionally, the participants were each assessed for progression of recovery, using the 
HBS, by an experienced clinician that was blinded to the treatment group allocation to 
reduce the risk for bias.10,11 
To fully assess for bias, financial or otherwise, a GRADE9 review was conducted 
on each of these trials.   The Health Technology Assessment (HTA)19, who acts to bridge 
the gap between policy making and evidence by examining the safety, efficacy and cost 
effectiveness primarily through research and RCTs, was solely responsible for the 
funding of the Sullivan et al study.11,19 Engström et al10 was funded by numerous entities 
including GlaxoSmithKline (GSK) and Pfizer AB of Sweden.  These pharmaceutical 
companies helped with the study design and also supplied the drugs for their study.  
Despite the obvious conflict of interest with their participation, the authors of this study 
openly admitted the involvement.  Additionally, the authors reported that none of the 
funding sources, including GSK and Pfizer had a role in the data collection or its analysis 
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and interpretation. In conclusion, due to the superb methodology of these trials, their 
completion of follow-up, and the consistency between their results, these trials should be 
considered of the highest quality.   
CONCLUSION 
  Corticosteroids (CS) have proven to increase the rate and overall amount of 
recoveries in patients with Bell’s palsy when initiated within the first 72 hours of 
symptom onset.  Despite the controversy surrounding a viral etiology, and the proposed 
benefit of using antivirals alone or in conjunction with CS, no quality RCTs have been 
published within the last five years to support that theory.  Additionally, both Engström10  
and Sullivan et al11 determined that the administration of antivirals actually slowed the 
rate of recovery when compared to treatment with CS or to no treatment at all.  The 
benefits of treatment with CS result in a NNT of eight in order to produce one more 
complete recovery.  The risks associated with a short course of CS treatment were 
reported to be very mild, and unless contraindicated for other medical conditions, the 
statistical significance of the evidence reported in these two trials should warrant the use 
of CS as the primary method of treatment.  The overall combined quality of the studies 
reviewed is high based on the GRADE criteria with no downgrading required.  A strong 
recommendation for the use of prednisone as the single pharmaceutical treatment can be 
made until further evidence reports a reliable difference in treatment outcome with 
antivirals or until a true etiology is established. 
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Table I: GRADE Quality of Assessment 
 
Quality Assessment 
Study Detail Downgrade Criteria Quality Comments 
Participants Design Limitations Indirectness Imprecision Inconsistency Publication 
Bias Likely 
  
 Engström et al (2008): RCT comparing Prednisolone and Valaciclovir 
839 RCT No serious 
limitations 
None 
identified 
None 
identified 
None 
identified 
 Not likely High Allocation concealment 
and blinding maintained 
until trial completion 
with minimal loss to 
follow up. 
Sullivan et al (2009): RCT comparing Prednisolone and Aciclovir 
 
551 RCT No serious 
limitations 
None 
identified 
None 
identified 
None 
identified 
Strongly 
unlikely 
High Allocation concealment 
and blinding maintained 
until trial completion 
with minimal loss to 
follow up.   
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Table II: Summary of Findings 
 
RCT Complete recovery of Bell’s palsy by time 
Engström et al  3 months 6 months 9 months 12 months 
Double placebo (OO) 111/206 
(54%) 
127/206 
(62%) 
__ 133/206 
(65%) 
Valaciclovir (VO) 113/207 
(55%) 
120/207 
(58%) 
__ 133/207 
(66%) 
Valaciclovir + 
Prednisolone (VP)
 
134/206 
(65%) 
149/206 
(72%) 
__ 164/206 
(80%) 
Prednisolone (OP) 137/210 
(65%) 
150/210 
(71%) 
__ 160/210 
(76%) 
Sullivan et al  3 months 6 months 9 months 12 months 
Double placebo (OO) 77/119 
(65%) 
__ 104/122 
(85%) 
__ 
Aciclovir (AO) 75/120 
(63%) 
__ 96/123 
(78%) 
__ 
Aciclovir + 
Prednisolone (AP) 
98/123 
(80%) 
__ 115/124 
(93%) 
__ 
Prednisolone (OP) 107/124 
(86%) 
__ 122/127 
(96%) 
__ 
 
 
 
 
 
 
 
 
